A new long-term study published by researchers at the University of Georgia, the Menzies Research Institute in Hobart, Australia and the Murdoch Childrens Research Institute in Melbourne, Australia suggests that waist circumference, rather than the commonly used body mass index measure, is the best clinical measure to predict a child's risk for cardiovascular disease and diabetes later in life.
Waist circumference predicts long-term cardio-metabolic health risks in children: Research
European Society of Cardiology to commence new programme of Global Scientific Activities at GW-ICC
On the opening day of today's Great Wall International Congress of Cardiology in Beijing the European Society of Cardiology (ESC) will take its first step in a new programme of Global Scientific Activities. The GW-ICC will host a one-day ESC educational programme built around highlights from the Society's annual meeting in Stockholm and this year's newly published ESC guidelines.
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
People who have been blind from birth make use of the visual parts of their brain to refine their sensation of sound and touch, according to an international team of researchers led by neuroscientists at Georgetown University Medical Center (GUMC).
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.